Please login to the form below

Not currently logged in
Email:
Password:

brivaracetam

This page shows the latest brivaracetam news and features for those working in and with pharma, biotech and healthcare.

UCB’s antiepileptic drug gains new US indication

UCB’s antiepileptic drug gains new US indication

The US Food and Drug Administration (FDA) has approved UCB’s Briviact (brivaracetam) CV as a monotherapy treatment option for epilepsy patients aged 16 years and older with partial-onset focal

Latest news

  • SMC gives green light for BMS’ Opdivo SMC gives green light for BMS’ Opdivo

    2014. Additionally, the SMC gave three further approvals to Lundbeck's antidepressant Brintellix (vortioxetine), Novartis' Cosentyx (secukinumab) for ankylosing spondylitis, and UCB's Briviact (brivaracetam) for partial-onset seizures in epilepsy

  • UCB bags FDA approval for epilepsy drug Briviact UCB bags FDA approval for epilepsy drug Briviact

    The US regulator has given the go-ahead to Briviact (brivaracetam) as an add-on treatment to other medications to treat partial onset seizures in patients aged 16 years and older ... Unlike many current epilepsy drugs, brivaracetam does not require dose

  • UCB wins European approval for epilepsy drug Briviact UCB wins European approval for epilepsy drug Briviact

    In trials, brivaracetam significantly reduced the frequency of seizures compared to placebo, with a 50% reduction in seizures seen in up to 40% of patients treated with UCB's drug. ... Unlike many current epilepsy treatments brivaracetam does not require

  • UCB boosted by core medicines growth UCB boosted by core medicines growth

    romosozumab for osteoporosis, lupus treatment epratuzumab, and brivaracetam for epilepsy.

  • UCB submits brivaracetam for use in epilepsy UCB submits brivaracetam for use in epilepsy

    UCB submits brivaracetam for use in epilepsy. Files drug in both the US and EU. ... A fourth phase III study evaluated the safety and tolerability of adjunctive brivaracetam given to patients with the same symptoms.

More from news
Approximately 3 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics